Aaron Kesselheim

Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital

[Aaron Kesselheim @akesselheim]

@ASLMENews @JLME_ASLME Congrats to contest winner @DrMarkLythgoe for a remarkably precisely accurate submission! Mark, I will email to process your prize. Thanks to everyone else for playing -- maybe next time!

[Aaron Kesselheim @akesselheim]

It's summer, so let's try another round of Where In The World Is @ASLMENews? As with last year, winner gets a year's membership, including a subscription to the world-famous journal, @JLME_ASLME (If you need a hint, the second photo provides some context for the first one)

[Aaron Kesselheim @akesselheim]

Happy to have the opportunity to hype this huge new piece that happened to hit on this holiday: led by @bnrome, a viewpoint on issues relating to the emergence (hooray!) of new biosimilar Humira: https://t.co/vfB4msanTP

[Aaron Kesselheim @akesselheim]

@statesdj @JAMAInternalMed @charliecwlee @bnrome @PORTAL_Research Thanks! If you email me I’ll get you a copy

[JAMA Internal Medicine @JAMAInternalMed]

Introduction of a citrate-free version of adalimumab in 2018 avoided Medicaid's inflationary rebates and led to >$4B excess spending from 2018-2021. https://t.co/tfhLYzQYTe @charliecwlee @akesselheim @bnrome @PORTAL_Research

[JAMA Health Forum @JAMAHealthForum]

New cross-sectional study finds that more than half of #AcceleratedApproval confirmatory trials are completed after the deadline set by the FDA. @akesselheim @bnrome @PORTAL_Research https://t.co/9ICDQ2IVBS

[Aaron Kesselheim @akesselheim]

Important session next week on racial discrimination and pulse oximetry in the @PORTAL_Research and Center for Bioethics health policy and bioethics consortium! Register please!

[MedPage Today @medpagetoday]

Despite new penalties via the #InflationReductionAct, drug companies raised prices for nearly 1k drugs in January. Is Congress' attempt to curb drug price hikes failing?

Read the #OpEd by Alexander C. Egilman, @akesselheim & @bnrome of @PORTAL_Research.
https://t.co/doSrzC6JnG

[Program On Regulation, Therapeutics, And Law @PORTAL_Research]

Thanks for a great presentation @sariahmed!

[JAMA Health Forum @JAMAHealthForum]

Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. @LSEHealthPolicy @PortalResearch @akesselheim @robinjforrest_ https://t.co/cZHnHts45L

[Ben Rome @bnrome]

Is It Business as Usual for the Drug Industry?

In @medpagetoday, Alex Egilman, @akesselheim, and I explain why drug companies continued to raise prices in 2023 despite the #InflationReductionAct

https://t.co/1RMQizACHj

[Aaron Kesselheim @akesselheim]

Watch @PORTAL_Research @AmeetSarpatwari speak at today's @SenateHELP hearing on COVID vaccine pricing -- and check out our @BostonGlobe op-ed from @DrHussainL on the public funding critical to its development: https://t.co/2EccXt3pp7

[Aaron Kesselheim @akesselheim]

New entry in the @NEJM Fundamentals of Health Law Series! Consolidation and competition in the health care sector -- and implications for patients and pricing; from Jaime King. Collect them all!: https://t.co/xns1mdechE

[Aaron Kesselheim @akesselheim]

Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee: https://t.co/jTNpp3j1Yc

[Boston Globe Opinion @GlobeOpinion]

Policy makers have several options to maximize benefits from public investments and improve returns for the entire global community, write @DrHussainL, Sarosh Nagar, Jerry Avorn, and @akesselheim.
https://t.co/D8fRt3HtIe

[NEJM @NEJM]

The FDA has long conducted its oversight of prescription drugs and other products with deference from courts. But mounting judicial skepticism of agency authority threatens to upend this norm. https://t.co/hhYGve4CTz

[William Feldman @wbfeldman]

Great article from @ZacharyBrennan
@endpts today covering our new work @Health_Affairs on inhaler patents and litigation.

Where are all the generic inhalers for asthma and COPD? Researchers call for patent and FDA reforms - https://t.co/DBpHYP0LUZ

[Harvard University @Harvard]

According to new findings, some of the most heavily advertised drugs are often no better at treating a disease than lesser known options https://t.co/SXM2apDHJq

[Ben Rome @bnrome]

Interesting point by @sean_r_dickson… maybe the new Medicaid rebate rules were one of the factors driving Lilly to lower list prices.

@akesselheim and I wrote about this in @JAMAInternalMed back in 2021: https://t.co/GX5Xp6ak1J

[Aaron Kesselheim @akesselheim]

Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee: https://t.co/jTNpp3j1Yc

[Aaron Kesselheim @akesselheim]

Our @NEJM Fundamentals of Health Law series continues with an overview of regulation and reproductive medicine from @ProfessorMutch: https://t.co/m7Qmn5Cu4N

[Aaron Kesselheim @akesselheim]

@Eddie_Cliff @PORTAL_Research @DrHussainL @AlexChaitoff @DavalJoseph @AdamR_UBC @frazer_tessema @oncology_bg @darioT_ Looking good, team!